03641nas a2200361 4500000000100000008004100001260001200042653001800054653003100072653003100103653003000134100001500164700001600179700001400195700002100209700001300230700001500243700002400258700001300282700002000295700001500315700001500330700001900345700001700364700001400381700001600395245016700411856009100578300000700669490000700676520258200683022001403265 2021 d c01/202110aHeterogeneity10aIndividual-based simulator10aSoil-transmitted helminths10aTransmission interruption1 aTruscott J1 aHardwick RJ1 aWerkman M1 aSaravanakumar PK1 aManuel M1 aAjjampur S1 aÁsbjörnsdóttir K1 aKhumbo K1 aWitek-McManus S1 aSimwanza J1 aCottrell G1 aHoungbégnon P1 aIbikounlé M1 aWalson JL1 aAnderson RM00aForecasting the effectiveness of the DeWorm3 trial in interrupting the transmission of soil-transmitted helminths in three study sites in Benin, India and Malawi. uhttps://parasitesandvectors.biomedcentral.com/track/pdf/10.1186/s13071-020-04572-7.pdf a670 v143 a
BACKGROUND: The DeWorm3 project is an ongoing cluster-randomised trial assessing the feasibility of interrupting the transmission of soil-transmitted helminths (STH) through mass drug administration (MDA) using study sites in India, Malawi and Benin. In this article, we describe an approach which uses a combination of statistical and mathematical methods to forecast the outcome of the trial with respect to its stated goal of reducing the prevalence of infection to below 2%.
METHODS: Our approach is first to define the local patterns of transmission within each study site, which is achieved by statistical inference of key epidemiological parameters using the baseline epidemiological measures of age-related prevalence and intensity of STH infection which have been collected by the DeWorm3 trials team. We use these inferred parameters to calibrate an individual-based stochastic simulation of the trial at the cluster and study site level, which is subsequently run to forecast the future prevalence of STH infections. The simulator takes into account both the uncertainties in parameter estimation and the variability inherent in epidemiological and demographic processes in the simulator. We interpret the forecast results from our simulation with reference to the stated goal of the DeWorm3 trial, to achieve a target of [Formula: see text] prevalence at a point 24 months post-cessation of MDA.
RESULTS: Simulated output predicts that the two arms will be distinguishable from each other in all three country sites at the study end point. In India and Malawi, measured prevalence in the intervention arm is below the threshold with a high probability (90% and 95%, respectively), but in Benin the heterogeneity between clusters prevents the arm prevalence from being reduced below the threshold value. At the level of individual study arms within each site, heterogeneity among clusters leads to a very low probability of achieving complete elimination in an intervention arm, yielding a post-study scenario with widespread elimination but a few 'hot spot' areas of persisting STH transmission.
CONCLUSIONS: Our results suggest that geographical heterogeneities in transmission intensity and worm aggregation have a large impact on the effect of MDA. It is important to accurately assess cluster-level, or even smaller scale, heterogeneities in factors which influence transmission and aggregation for a clearer perspective on projecting the outcomes of MDA control of STH and other neglected tropical diseases.
a1756-3305